MedTrace Logo

Real-life Effectiveness and Cost-effectiveness of Qvar Versus FP and BDP in the Management of COPD

NCT01141452 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 815377

Last updated 2011-03-08

No results posted yet for this study

Summary

The objective of this study is to compare the effectiveness, cost-effectiveness and direct healthcare costs of managing chronic obstructive pulmonary disease (COPD) in primary care patients with evidence of COPD who either initiate inhaled corticosteroid (ICS) therapy, or have an increase in their ICS dose, as hydrofluoroalkane (HFA) beclometasone dipropionate (BDP) (hereafter Qvar®), CFC-BDP (hereafter BDP) and fluticasone propionate (FP) via pressurised metered-dose inhalers.

Conditions

Interventions

DRUG

Extra-fine hydrofluoroalkane beclomethasone MDI

Step-up in baseline BDP-equivalent ICS dose

DRUG

Chlorofluorocarbon beclomethasone metered dose inhaler

Step-up in baseline BDP-equivalent ICS dose

DRUG

Fluticasone propionate metred dose inhaler

Step-up in baseline BDP-equivalent ICS dose

DRUG

Fluticasone propionate metred dose inhaler

Initiation of ICS therapy

DRUG

Hydrofluoroalkane beclomethasone metred dose inhaler

Initiation of ICS therapy

DRUG

Chlorofluorocarbon beclomethasone dipropionate

Initiation of ICS therapy

Sponsors & Collaborators

  • Teva Branded Pharmaceutical Products R&D, Inc.

    collaborator INDUSTRY

  • Research in Real-Life Ltd

    lead NETWORK

Principal Investigators

  • David Price, Prof. MD · Company Director

  • Alison Chisholm, MSc · Research Project Director

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-01-31
Primary Completion
2007-06-30
Completion
2007-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01141452 on ClinicalTrials.gov